Chemed (CHE) opened Q1 2026 with revenue of US$657.5 million and basic EPS of US$4.85, while trailing twelve month figures show revenue of US$2.5b and basic EPS of US$18.34. Over the past year, revenue has ranged from US$618.8 million to US$646.9 million in the 2025 quarters, with basic EPS moving between US$3.60 and US$5.48 across the same periods. This gives investors a clear view of how the current print fits into a steady recent run. With net profit margin at 10.2% over the trailing twelve months versus 12.4% a year earlier, the focus now turns to how durable the margin profile looks against the current growth narrative.
See our full analysis for Chemed.With the headline numbers in place, the next step is to line them up against the prevailing stories around Chemed to see which narratives the latest quarter supports and which ones the margin trends start to question.
See what the community is saying about Chemed
Net income trends over recent quarters
- Net income excluding extra items came in at US$66.3 million for Q1 2026, compared with a range of US$52.5 million to US$90.3 million over the last five reported quarters.
- Consensus narrative views long term growth as supported by expansion in hospice services and efficiency efforts, and this income range gives you a reality check on that view, as:
- VITAS growth catalysts and Roto Rooter cash flow are expected in the consensus story to support higher earnings over time, yet trailing twelve month net income of US$259.8 million sits below the US$302.0 million level reported for the year ending Q4 2024.
- The same consensus narrative expects margin improvements as operational changes kick in, while the trailing net profit margin is 10.2% compared with 12.4% a year earlier, so investors can see current profitability still catching up with that outlook.
Margins under pressure despite high quality earnings
- Over the trailing twelve months, basic EPS is US$18.34 on revenue of about US$2.5b, with a net profit margin of 10.2% versus 12.4% a year earlier, which frames how much of each revenue dollar is currently turning into profit.
- Consensus narrative suggests operational efficiency and technology investment should help margins, and the mix of strong EPS and softer margin backs and tests that claim at the same time, because:
- Trailing twelve month EPS of US$18.34 compares with US$20.10 for the year ending Q4 2024, so earnings per share have softened while still being assessed as high quality, which lines up only partly with the expectation of margin expansion.
- The consensus view highlights reimbursement and cost risks at both VITAS and Roto Rooter, and the move from a 12.4% to 10.2% net margin over the last year shows those pressures are visible in the numbers investors are working with today.
DCF fair value and analyst targets versus price
- With the share price around US$423.94, Chemed is described as trading about 38.6% below a DCF fair value estimate of roughly US$690.99, and analysts using a price target of US$446.50 are only about 5.3% above the current price, which highlights a gap between modelled value and price targets.
- Bullish narrative leans on higher long term earnings and margins to justify upside, and the current valuation mix both supports and challenges that, because:
- The stock trades on a P/E of 21.6x versus 24.3x for the US Healthcare industry and 49.4x for peers, which bullish investors can point to as a discount while also noting that trailing five year earnings have slipped by 0.6% per year.
- Bulls reference forecast earnings growth of about 12.9% a year and revenue growth of 6.3% a year, yet the drop in trailing net margin and lower recent EPS compared with a year earlier means the market may be waiting for more consistent delivery before closing the gap to DCF fair value or analyst targets.
For a deeper look at how bullish investors connect these earnings, margin trends, and valuation gaps into a long term thesis, check out the 🐂 Chemed Bull Case
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Chemed on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
Seen enough contrasting signals for Chemed and still unsure where you stand? Take a closer look at the data, evaluate the earnings, margins, and valuation for yourself, and then round out your view with 3 key rewards and 1 important warning sign
See What Else Is Out There
Chemed is facing pressure from softer net margins, trailing EPS below last year, and a disconnect between DCF fair value, analyst targets, and current earnings delivery.
If that mix of margin strain and valuation uncertainty leaves you cautious, you can compare it with companies that look cheaper on the numbers using the 52 high quality undervalued stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com